CoChat

Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy

Open access
Zeballos C., M. Alejandra, Gaj, Thomas · 2021 · Trends in Biotechnology
Cited by 94

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

The emergence of CRISPR nucleases has transformed biotechnology by providing an easy, efficient and versatile platform for editing DNA. However, traditional CRISPR-based technologies initiate editing by activating DNA double-strand break repair pathways, which can cause adverse effects in cells and restrict certain therapeutic applications of the technology. To this end, several new CRISPR-based modalities have been developed that are capable of catalyzing editing without the requirement for a double-strand break. Here we review three of these technologies – base editors, prime editors and RNA-targeting Cas13 effectors. We discuss their strengths compared to traditional gene-modifying systems, we highlight their emerging therapeutic applications, and we examine challenges facing their safe and effective clinical implementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2020.10.010

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 94

Metadata

Authors
Zeballos C., M. A., & Gaj, T.
Venue
Trends in Biotechnology
Publisher
Elsevier BV
Published
2021-07
Volume
39
Issue
7
Pages
692-705
ISSN
0167-7799 (ISSN-L)
OpenAlex
W3109253806
Cited by
94
References
46
FWCI
1.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. https://app.cochat.ai/papers/10.1016/j.tibtech.2020.10.010
The paper
Zeballos C., M. A., & Gaj, T. (2021). Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2020.10.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.